Cytokinetics (CYTK) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to -$1.0 billion.
- Cytokinetics' Enterprise Value fell 8755.39% to -$1.0 billion in Q3 2024 from the same period last year, while for Sep 2024 it was -$1.0 billion, marking a year-over-year decrease of 8755.39%. This contributed to the annual value of -$615.2 million for FY2023, which is 2154.85% up from last year.
- Latest data reveals that Cytokinetics reported Enterprise Value of -$1.0 billion as of Q3 2024, which was down 8755.39% from -$1.1 billion recorded in Q2 2024.
- Cytokinetics' Enterprise Value's 5-year high stood at -$213.1 million during Q2 2020, with a 5-year trough of -$1.1 billion in Q2 2024.
- Its 5-year average for Enterprise Value is -$576.6 million, with a median of -$566.1 million in 2023.
- In the last 5 years, Cytokinetics' Enterprise Value crashed by 14708.89% in 2020 and then surged by 3780.84% in 2023.
- Over the past 5 years, Cytokinetics' Enterprise Value (Quarter) stood at -$464.1 million in 2020, then decreased by 1.63% to -$471.6 million in 2021, then plummeted by 66.27% to -$784.2 million in 2022, then grew by 21.55% to -$615.2 million in 2023, then crashed by 64.51% to -$1.0 billion in 2024.
- Its Enterprise Value was -$1.0 billion in Q3 2024, compared to -$1.1 billion in Q2 2024 and -$619.3 million in Q1 2024.